Emergent BioSolutions Inc. today announced that it has been awarded approximately $23 million to develop a novel multi-drug auto-injector for nerve agent antidote delivery. Emergent’s device is being designed for intramuscular self- [Read more]
The only FDA-licensed smallpox vaccine, ACAM2000 (Smallpox (Vaccinia) Vaccine, Live), will be acquired from Sanofi by Emergent BioSolutions under a recently announced deal. The move expands and diversifies Emergent’s portfolio of medical [Read more]
Supported by BARDA, CARB-X and big pharma, Superbugs & Superdrugs USA will provide insight into both traditional and non-traditional approaches towards combatting AMR whilst looking at financing initiatives and keeping attendees at [Read more]
Antibiotic resistance is one of the most significant global public health problems and is rising in many developing nations due to over-use of antimicrobial agents, widespread availability of counterfeit or substandard medicines [Read more]
The Defense Biological Product Assurance Office (DBPAO), a component of the Joint Program Executive Office for Chemical and Biological Defense, has announced the development of a Biological Select Agents and Toxins (BSAT) [Read more]
The Defense Threat Reduction Agency Joint Science and Technology Office’s (JSTO) Toxicant Penetration and Scavenging (TPS) research program, managed by Brian Pate, Ph.D., explores countermeasure development for increased protection against chemical and biological weapons. [Read more]
A clinical trial of an experimental vaccine to prevent infection with chikungunya virus is now enrolling healthy adult volunteers at sites in the United States. The Phase 1/2 trial, which is sponsored [Read more]
The Biomedical Advanced Research and Development Authority (BARDA) has announced intentions to award a research and development contract to Evolva in support of a “Novel Toxicant and Repellent for Arthropod-borne Virus Vectors (NTRAVV)”. [Read more]
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Virology Division, Pathogenesis and Immunology Branch has been tasked by the Defense Threat Reduction Agency to investigate a potential for enhanced efficacy [Read more]
The U.S. Army Medical Research and Materiel Command (USAMRMC) Special Immunizations Program (SIP) currently offers Investigational New Drug (IND) products to both military and civilian personnel at risk for pathogen and toxin exposure. [Read more]
© 2017 Global Biodefense